The efficacy and safety of tadalafil: An update

BJU International

Volumn 93, Issue 9, 2004, Pages 1276-1281

  Carson, C C ^a   Rajfer, J ^b   Eardley, I ^c   Carrier, S ^d   Denne, J S ^e   Walker, D J ^e   Shen, W ^e   Cordell, W H ^e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d MCGILL UNIVERSITY   (Canada)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Efficacy; Erectile dysfunction; Impotence; Penile erection; Tadalafil

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; TADALAFIL; CARBOLINE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR;

ADULT; AGED; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MYALGIA; NOSE CONGESTION; PENIS ERECTION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEXUAL INTERCOURSE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; ARTICLE; COITUS; IMPOTENCE; META ANALYSIS; MIDDLE AGED; PATIENT SATISFACTION;

ADULT; AGED; AGED, 80 AND OVER; CARBOLINES; COITUS; DOUBLE-BLIND METHOD; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHOSPHODIESTERASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 2942711783     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04819.x     Document Type: Review

References (19)

1. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. IJIR 2000; 12: S6-S11
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61
3. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003; 62: 121-6
4. Brock GB, McMahon CG, Chen KK et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332-6
5. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30
6. Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002; 60: 12-27
7. Saenz dTI, Knight JR, Anglin G, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25: 2159-64
8. Montorsi F, McCullough A, Brock G et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve-sparing radical retropubic prostatectomy. IJIR 2003; 15: S170-1
9. Padma-Nathan H, Rosen RC, Shabsigh R, Saikali K, Watkins V. Tadalafil (IC351) provides prompt and extended period of response for the treatment of men with ED. IJIR 2001; 13: S64
10. Padma-Nathan H, Stecher VJ, Sweeney M, Orazem J, Tseng L-J, de Riesthal H. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003; 62: 400-3
11. Hellstrom WJG. Vardenafil: a new approach to the treatment of erectile dysfunction. Curr Urol Rep 2003; 4: 479-87
12. Patterson B, Bedding A, Jewell H, Payne C, Mitchell M. The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). IJIR 2001; 13: S43
13. Muirhead GJ, Allen MJ, James CG et al. Pharmacokinetics of sildenafil (Viagra), a selective cQMP PDE5 inhibitor, after single oral doses in fasted and fed healthy volunteers. Br J Clin Pharmacol 1996; 42: 268
14. Jetter A, Kinzig-Schippers M, Walchner-Bonjean M et al. Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther 2002; 71: 21-9
15. Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003; 43: 260-7
16. Montorsi F, Verheyden B, Meuleman E et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004; 45: 339-45
17. Emmick JT, Stuewe SR, Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur Heart J 2002; 4 (Suppl): H32-H47
18. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol 2003; 92: 37-46
19. Hellstrom WJG, Overstreet JW, Yu A et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 2003; 170: 887-1